Eytan Abraham (Lonza (Group))

Abraham, Eytan (Lonza 201710 RnD Associate Director)

	Organisation	Lonza (Group)
	Former/major organisation	Lonza Collaborative Innovation Center (CIC) (Haifa, IL)
	Group	Lonza (Group)
	Product	contract manufacturing (biologicals)

Lonza Group AG. (10/9/17). "Press Release: Lonza Announces Formation of New Research and Development Collaborative Innovation Center in Israel". Basel.

Lonza today announced the establishment of the Lonza Collaborative Innovation Center (CIC) in the new Life Science Park in the outskirts of Haifa, Israel.

The CIC will begin operating in Q4 2017 and span close to 1,000 square meters. It is expected to hire 15-20 staff members in 2018 to leverage Israel’s scientific strengths in areas such as engineering, software and cell/molecular biology to provide Lonza opportunities to gain additional know-how and capabilities. With the launch of the CIC, Lonza aims to accelerate leading Research & Development (R&D) projects from across Lonza's Pharma&Biotech segment, as well as tap into potentially transformative biological and manufacturing capabilities.

“Through its growing reputation as a biotech hub, Israel offers Lonza an opportunity to expand our capabilities and bring transformative technologies and offerings to Lonza Pharma&Biotech customers. That's why we chose to establish the Lonza Collaborative Innovation Center in Israel,” said Marc Funk, COO for Lonza's Pharma&Biotech segment, who is the chairman of the board of the newly incorporated local entity.

“At Lonza we enable our customers to meet some of the greatest challenges in patient treatment. The medicines and research tools of tomorrow are often highly complex, posing new challenges to the way they can be developed and manufactured," he added.

The CIC will have a dedicated Lonza R&D team in Israel, who will work with local industry and academic experts through collaborations and sponsored research. Lonza has already signed memorandums of understanding and conducted talent scouting at Tel Aviv University, Technion R&D Foundation and the Weizmann Institute of Science.

"Lonza strives to work with the brightest talent in house and through collaborations with leading scientists and companies to ensure our position as the leading pharma and biotech CDMO and bioresearch provider," Funk said. "We aim to be at the forefront of providing the appropriate innovative technologies in order to manufacture medicines safely and in a timely manner and to deliver the medicines of tomorrow, today."

Eytan Abraham, Research & Development Associate Director at Lonza, will take responsibility for setting up the center. Roee Atlas has been recently hired to manage the center.

About Lonza

Following the closing of the Capsugel acquisition, Lonza further strengthened its position as one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

An integrated solutions provider serving the healthcare continuum, Lonza offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. In addition to drinking water sanitizers, nutraceuticals, antidandruff agents and other personal care ingredients, the company provides agricultural products, advanced coatings and composites and microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a wellrespected global company with more than 50 major manufacturing and R&D facilities and nearly 14,000 full-time employees worldwide. Further information can be found at www.lonza.com.

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forwardlooking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

Lonza Contact Details

Dirk Oehlers, Head Investor Relations Lonza Group Ltd Tel +41 61 316 8540 dirk.oehlers@lonza.com

Dominik Werner, Head Corporate Communications Lonza Group Ltd Tel +41 61 316 8798 dominik.werner@lonza.com

Constance Ward, Head External Communications Lonza Group Ltd Tel +41 61 316 8840 constance.ward@lonza.com